Search Results

Endo International plc reported financial results for the fourth-quarter ended December 31, 2023.

Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen’s (formerly Horizon Therapeutics) DUEXIS®.

Endo, Inc. announced that the Company has commenced trading on the OTCQX® Best Market under the ticker symbol NDOI.

Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study.

Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren’s contracture and XIAFLEX ® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.

InnoGI Technologies, a pioneer and leader in innovative gastrointestinal research, proudly announces the appointment of Dr. Hajime Endo as its Strategic Commercial Advisor.

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer.

Ascendis Pharma A/S announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024.